Highlights

    Please wait a minute...
    For Selected: Toggle Thumbnails
    China Alzheimer Report 2024
    WANG Gang, QI Jinlei, LIU Xinya, REN Rujing, LIN Shaohui, HU Yisong, LI Haixia, XIE Xinyi, WANG Jintao, LI Jianping, ZHU Yikang, GAO Mengyi, YANG Junjie, WANG Yiran, JING Yurong, GENG Jieli, ZHI Nan, CAO Wenwei, XU Qun, YU Xiaoping, ZHU Yuan, ZHOU Ying, WANG Lin, GAO Chao, LI Binyin, CHEN Shengdi, YUAN Fang, DOU Ronghua, LIU Xiaoyun, LI Xuena, YIN Yafu, CHANG Yan, XU Gang, XIN Jiawei, ZHONG Yanting, LI Chunbo, WANG Ying, ZHOU Maigeng, CHEN Xiaochun, representing the China Alzheimer's Disease Report Writing Group
    Journal of Diagnostics Concepts & Practice    2024, 23 (03): 219-256.   DOI: 10.16150/j.1671-2870.2024.03.001
    Abstract10671)   HTML750)    PDF(pc) (3340KB)(8089)       Save

    With the sustained growth of economy and significant changes in social demographics, the issue of elderly-related diseases has increasingly drawn attention particularly. Alzheimer's disease (AD),as a representative disease of neurodegenerative diseases has become a major challenge, affecting the health and quality of life among the elderly population severely. In recent years, the incidence, prevalence, and mortality rate of AD increase in China, imposing substantial economic burdens on families, society, and the entire healthcare system. To proactively address this challenge and respond to the national 'Healthy China Action' initiative, leading experts from Renji Hospital, Shanghai Jiao Tong University School of Medicine,and Chinese Center for Disease Control and Prevention Chronic Non-communicable Disease Control Center, Fudan University School of Public Health, Shanghai Mental Health Center, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Fujian Medical University, and other authoritative institutions, have jointly authored the 'China Alzheimer Disease Report 2024'. Building upon previous editions of 2021, 2022, and 2023, this report updates epidemiological data on AD in China, thoroughly analyzes the latest economic burdens of the disease, and comprehensively evaluates the current status of AD diagnosis and treatment services, as well as the allocation of public health resources in our country. The release of the 'China Alzheimer Disease Report 2024' not only reflects China's progress and efforts in AD research and prevention, but also underscores the social heightened concern for elderly health issues. It aims to provide scientific and technical guidance and robust data support for the prevention, diagnosis, and treatment of AD, offering a professional basis for the government and relevant departments to formulate targeted health policies and intervention measures. Furthermore, it serves as a platform for promoting academic exchanges and cooperation in this field domestically and internationally. Through the dissemination and application of this report, we anticipate it will not only serve as a reference for professionals but also enhance public awareness of AD, promote active participation across various sectors of society, and jointly advance the development of elderly health care in China, empowering us towards achieving 'healthy aging'.

    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Interpretation on the report of global stroke data 2022
    TANG Chunhua, GUO Lu, LI Qiong, ZHANG Lili
    Journal of Diagnostics Concepts & Practice    2023, 22 (03): 238-246.   DOI: 10.16150/j.1671-2870.2023.03.06
    Abstract6515)   HTML261)    PDF(pc) (2270KB)(5174)       Save

    In 2022, the World Stroke Organization released two new reports regarding global stroke statistics in the International Journal of Stroke. The reports updated the global incidence and mortality of stroke, evaluated the effects of gender and geographic factors, and provided updated statistics on attributable risk factors associated with stroke. This article briefly interprets the two reports in the context of stroke prevalence and disease burden in China. 2019 Global Burden of Disease Study findings show that stroke remains the second-leading cause of death and the third-leading cause of death and disability combined in the world. From 1990 to 2019, the burden (in terms of the absolute number of cases) increased substantially, with the bulk of the global stroke burden residing in lower-income and lower-middle-income countries. Moreover, people under 70-year-old were observed to have significant increases in stroke prevalence and incidence. The five major risks for stroke globally include high systolic blood pressure, high body mass index, high fasting glucose, environmental particulate matter pollution, and smoking. Stroke prevention and treatment in China are facing great challenges. Stroke has become the leading cause of death and disability among Chinese adults, as well as the leading cause of disability adjusted life year lost. The incidence, prevalence and mortality of stroke in China are geographically high in the north, low in the south and prominent in the central part of the country; the prevalence is higher in rural areas than that in urban areas; the morbidity and mortality rates are higher in men than those in women; the average age of onset is lower than in developed countries; the overall disease burden of ischemic stroke is on the rise, but that of hemorrhagic stroke is on the decline. The awareness of stroke prevention and treatment was low. In conclusion, it is of strategic importance to actively establish a graded stroke prevention and control system that meets the national conditions.

    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Interpretation of the Global Tuberculosis Report 2022 by World Health Organization
    LIANG Chen, YU Jiajia, TANG Shenjie
    Journal of Diagnostics Concepts & Practice    2023, 22 (01): 21-30.   DOI: 10.16150/j.1671-2870.2023.01.004
    Abstract2003)   HTML56)    PDF(pc) (1105KB)(4153)       Save

    Global Tuberculosis Report 2022 (hereafter referred to as “report”), newly published by the World Health Organization (WHO), states that the coronavirus (COVID-19) pandemic has increased the tuberculosis (TB) disease burden and severely affected global TB prevention and control. In 2021, WHO approved a total of six molecular diagnostic technologies for TB diagnosis and anti-TB drug resistance detection, and three new TB antigen-based skin tests for TB screening were recommended. To reduce the burden on patients and the health system, WHO recommends a 4-month regimen for drug-susceptible TB and four shorter regimens for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). In addition, there were 26 drugs for TB treatment in clinical trials, and at least 22 clinical trials evaluating drugs and drug regimens for TB treatment were underway. In 2021, the TB epidemic remains severe in China, with the number of newly diagnosed cases ranking third among the 30 countries. In 2021, a total of 639 548 TB cases and 1 763 deaths were reported nationwide, with an incidence of 45.37/100 000 and a mortality of 0.13/100 000. China has the fourth largest number of MDR/RR-TB patients in the world. However, it is necessary to verify whether the regimens for MDR/RR-TB treatment recommended by WHO are suitable for patients in China.

    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Treatment of patients with severe basic diseases combined with infection of novel coronavirus Omicron variant
    Diagnosis and Treatment of COVID-19 from Expert Group of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Journal of Diagnostics Concepts & Practice    2022, 21 (02): 105-117.   DOI: 10.16150/j.1671-2870.2022.02.001
    Abstract464)   HTML37)    PDF(pc) (1649KB)(139)       Save
    Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2022, 21 (01): 5-7.   DOI: 10.16150/j.1671-2870.2022.01.002
    Abstract828)   HTML29)    PDF(pc) (345KB)(414)       Save
    Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2022, 21 (01): 22-31.   DOI: 10.16150/j.1671-2870.2022.01.006
    Abstract403)   HTML17)    PDF(pc) (1156KB)(232)       Save
    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2021, 20 (04): 317-337.   DOI: 10.16150/j.1671-2870.2021.04.001
    Abstract11716)   HTML621)    PDF(pc) (3337KB)(10341)       Save
    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2021, 20 (04): 349-355.   DOI: 10.16150/j.1671-2870.2021.04.004
    Abstract1200)   HTML33)    PDF(pc) (766KB)(2176)       Save
    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2021, 20 (01): 8-14.   DOI: 10.16150/j.1671-2870.2021.01.002
    Abstract656)   HTML24)    PDF(pc) (806KB)(195)       Save
    Table and Figures | Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2021, 20 (02): 144-148.   DOI: 10.16150/j.1671-2870.2021.02.005
    Abstract344)   HTML10)    PDF(pc) (687KB)(322)       Save
    Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2020, 19 (02): 101-103.   DOI: 10.16150/j.1671-2870.2020.02.001
    Abstract915)   HTML9)    PDF(pc) (363KB)(426)       Save
    Reference | Related Articles | Metrics | Comments0
    Journal of Diagnostics Concepts & Practice    2020, 19 (02): 104-110.   DOI: 10.16150/j.1671-2870.2020.02.002
    Abstract673)   HTML5)    PDF(pc) (574KB)(251)       Save
    Table and Figures | Reference | Related Articles | Metrics | Comments0